Radiotherapy in Oligometastatic Prostate Cancer
Cette étude passe en revue les essais cliniques concernant l'utilisation de la radiothérapie chez les patients atteints d'un cancer de la prostate oligométastatique
Prostate cancer ranges from localized, low risk to metastatic, morbid disease. While radiotherapy is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized radiotherapy in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of radiotherapy as an immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering radiotherapy in metastatic disease.
International Journal of Radiation Oncology, Biology, Physics 2022